Loading...
•
Dec 31, 2021
Harrow Q4 2021 Earnings Report
Reported sixth consecutive quarter of record revenues and improved gross margin.
Key Takeaways
Harrow Health reported record revenues for the fourth quarter of 2021, marking the sixth consecutive quarter of record performance. The company also achieved a gross margin of 75% during the quarter.
Reported sixth consecutive quarter of record revenues.
Gross margin improved to 75% for the fourth quarter.
Filed first New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).
Began to realize high-margin revenues from recently acquired FDA-approved branded products.
Forward Guidance
2022 is shaping up to be a ‘break-out’ year for Harrow Health. In the second quarter of 2022, the company is expecting top-line readouts on clinical studies from two of their non-controlling equity positions, followed in mid-October by a determination by the FDA on their NDA for AMP-100.
Positive Outlook
- Expecting top-line readouts on clinical studies from two of our non-controlling equity positions in the second quarter of 2022.
- FDA determination expected in mid-October on NDA for AMP-100.
- Potential commercial launch a few months after FDA approval.
- Focus on growing core ophthalmic pharmaceuticals business.
- Launching new ophthalmic products internally developed.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...